Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET)

被引:8
作者
Andreasi, Valentina [1 ,4 ]
Partelli, Stefano [1 ,4 ]
Manzoni, Marco [2 ]
Muffatti, Francesca [1 ,4 ]
Colombo, Barbara [3 ]
Corti, Angelo [3 ,4 ]
Falconi, Massimo [1 ,4 ]
机构
[1] Ist Sci San Raffaele, Pancreas Translat & Clin Res Ctr, Pancreat Surg Unit, Milan, Italy
[2] Ist Sci San Raffaele, Endocrinol Unit, Milan, Italy
[3] Ist Sci San Raffaele, Expt Oncol Div, Milan, Italy
[4] Vita & Salute Univ, Milan, Italy
关键词
Biomarkers; Chromogranin A; Pancreatic neuroendocrine tumor; Vasostatin-1; CIRCULATING CHROMOGRANIN-A; CLINICAL UTILITY; PROGNOSTIC VALUE; DIAGNOSTIC-VALUE; FOLLOW-UP; MARKER; SIZE;
D O I
10.1016/j.pan.2018.11.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: A reliable and accessible biomarker for nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET) is currently unavailable. Chromogranin A (CgA) represents the best-described neuroendocrine biomarker, but its accuracy is low. Vasostatin-1 (VS-1), a fragment derived from the cleavage of CgA, was recently investigated and found to be more accurate as tumor biomarker in a cohort of patients affected by mainly metastatic small intestinal NET. Methods: Patients submitted to surgery for sporadic localized NF-PanNET at San Raffaele Hospital were included. Preoperative plasma samples were prospectively collected. Circulating levels of total-CgA and VS-1 were retrospectively investigated by sandwich Enzyme-Linked ImmunoSorbent Assays. Results: Overall, 50 patients were included. VS-1 value (P=0.0001) was the only preoperatively retrievable factor independently associated with NF-PanNET size. No significant correlation between CgA and tumor diameter was found (P = 0.057). A VS-1 value of 0.39 nM was identified as the optimal VS-1 cut-off accurately associated with NF-PanNET larger than 4 cm. Patients with VS-1 > 0.39 nM had a significantly higher frequency of microvascular invasion (P= 0.005) and nodal metastasis (P = 0.027). Median VS-1 plasma level was significantly higher in the presence of microvascular invasion (P = 0.001) and nodal metastasis (P= 0.012). PPI assumption significantly increased total-CgA levels, but not those of VS-1 (P = 0.111). Conclusions: In localized, non-metastatic NF-PanNET, VS-1 is strongly associated to tumor dimension and its plasma levels are significantly higher in the presence of microvascular invasion and nodal metastases; moreover, VS-1 value is not affected by the PPI use. (C) 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 35 条
[1]   Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study [J].
Bachetti, Tiziana ;
Bardile, Alberto Ferrari ;
Aloi, Teresa Lucia ;
Colombo, Barbara ;
Assi, Emma ;
Savino, Giuseppina ;
Vercelli, Andrea ;
Colombo, Roberto ;
Corti, Angelo .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 236 :438-443
[2]   Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor [J].
Bettini, Rossella ;
Partelli, Stefano ;
Boninsegna, Letizia ;
Capelli, Paola ;
Crippa, Stefano ;
Pederzoli, Paolo ;
Scarpa, Aldo ;
Falconi, Massimo .
SURGERY, 2011, 150 (01) :75-82
[3]  
Bossuyt PM, 2015, BMJ-BRIT MED J, V351, DOI [10.1148/radiol.2015151516, 10.1373/clinchem.2015.246280, 10.1136/bmj.h5527]
[4]   Chromogranin A in heart failure - A novel neurohumoral factor and a predictor for mortality [J].
Ceconi, C ;
Ferrari, R ;
Bachetti, T ;
Opasich, C ;
Volterrani, M ;
Colombo, B ;
Parrinello, G ;
Corti, A .
EUROPEAN HEART JOURNAL, 2002, 23 (12) :967-974
[5]   Development of an immunoassay for the derived-peptide of chromogranin A, Vasostatin-I (1-76): assessment of severity in patients with sepsis [J].
Chung, Helene ;
Corti, Angelo ;
Crippa, Luca ;
Schneider, Francis ;
Metz-Boutigue, Marie-Helene ;
Garnero, Patrick .
BIOMARKERS, 2012, 17 (05) :430-434
[6]   Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms [J].
Corsello, Andrea ;
Di Filippo, Luigi ;
Massironi, Sara ;
Sileo, Federica ;
Capuzzo, Anna Dolcetta ;
Gemma, Marco ;
Carlucci, Claudia ;
Cusini, Claudio ;
Colombo, Barbara ;
Dallatomasina, Alice ;
Franchi, Giulia Maria ;
Corti, Angelo ;
Manzoni, Marco Federico .
PLOS ONE, 2018, 13 (05)
[7]   Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States [J].
Dasari, Arvind ;
Shen, Chan ;
Halperin, Daniel ;
Zhao, Bo ;
Zhou, Shouhao ;
Xu, Ying ;
Shih, Tina ;
Yao, James C. .
JAMA ONCOLOGY, 2017, 3 (10) :1335-1342
[8]   Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-α-elicited endothelial activation [J].
Di Comite, Gabriele ;
Rossi, Carlo M. ;
Marinosci, Alessandro ;
Lolmede, Karine ;
Baldissera, Elena ;
Aiello, Patrizia ;
Mueller, Ruediger B. ;
Herrmann, Martin ;
Voll, Reinhard E. ;
Rovere-Querini, Patrizia ;
Sabbadini, Maria Grazia ;
Corti, Angelo ;
Manfredi, Angelo A. .
JOURNAL OF LEUKOCYTE BIOLOGY, 2009, 85 (01) :81-87
[9]   Non-functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 Patients [J].
Franko, Jan ;
Feng, Wentao ;
Yip, Linwah ;
Genovese, Elizabeth ;
Moser, A. James .
JOURNAL OF GASTROINTESTINAL SURGERY, 2010, 14 (03) :541-548
[10]   Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine [J].
Fuksiewicz, Malgorzata ;
Kowalska, Maria ;
Kolasinska-Cwikla, Agnieszka ;
Cwikla, Jaroslaw B. ;
Sawicki, Lukasz ;
Roszkowska-Purska, Katarzyna ;
Drygiel, Joanna ;
Kotowicz, Beata .
ENDOCRINE CONNECTIONS, 2018, 7 (06) :803-810